Keywords: otsuka, buys, pdl, busulfex, 200m, japan, pharmaceutical
Otsuka buys PDL's Busulfex for $200M
Article | 24 December 2007
Japan's Otsuka Pharmaceutical has entered into a definitive agreement to acquire the rights to USA-based PDL BioPharma's IV Busulfex (busulfan), ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
